The original news link in Chinese:
<a href="https://i.ifeng.com/c/8DWIVQHnFid">https://i.ifeng.com/c/8DWIVQHnFid</a>

Chemexpress (SHA:688131) and MindRank strengthen cooperation in AI-enabled Drug Discovery

The original news link:
<a href="https://www.prnewswire.com/news-releases/mindrank-begins-ind-enabling-studies-of-its-first-ai-designed-drug-8-months-after-program-initiation-301462526.html">MindRank Begins IND-enabling Studies of its first AI-designed Drug, 8 Months After Program Initiation (prnewswire.com)</a>
<img src="https://api.site.mindrank.ai/v1/files/45c0fe3a-c9bb-45ae-83f9-30fb8f3f3957" alt="" width="1080" height="459" />
MindRank AI, an artificial intelligence (AI) driven biotech company, today announced that the company has nominated a preclinical candidate (PCC) for a class B GPCR drug target&nbsp;within&nbsp;8 Months of Program Initiation. Historically, the development of small-molecule agonists of class B GPCRs has been proven particularly challenging.
Empowered by Mindrank&rsquo;s proprietary AI drug discovery platform, Molecule Pro, fewer than 100 proprietary compounds were synthesized and tested, and some of them have undergone extensive characterization both in vitro and in vivo. MindRank&rsquo;s team has identified several drug candidates with potential for best-in-class characteristics for multiple chronic disease indications with large unmet medical needs. The drug candidates have excellent functional potency and selectivity, favorable ADME properties and oral bioavailability, desirable pharmacokinetics, and safety profiles. They also showed robust preclinical efficacy and good tolerability in several disease-relevant animal models.
This is the second drug candidate that has initiated investigational new drug (IND)-enabling studies since the company&rsquo;s inception within less than one year. MindRank has successfully delivered an allosteric inhibitor PCC with best-in-class potential within a few months since the program was initiated as a collaboration with a publicly-traded biotech company, which started IND-enabling studies in September 2021.
&ldquo;Our platform has greatly improved the efficiency of drug discovery. We strive to push the boundaries of AI for drug discovery by continuous innovations,&rdquo; commented Zhangming Niu, Founder, and CEO of MindRank.
The Mindrank team includes senior medicinal chemists, molecular biologists, and AI drug research and development experts. The team members have successfully discovered 16 targets and led multiple drug pipelines into clinical trials, some of which have been listed. In 2021, MindRank has completed an Angle round of 45 million Yuan and Series A round financing of tens of millions of US dollars.

MindRank begins IND-enabling studies of its first AI-designed drug, eight months after program initiation

The original publication link:&nbsp;
<a href="https://www.nature.com/articles/s41551-021-00819-5">Amelioration of Alzheimer&rsquo;s disease pathology by mitophagy inducers identified via machine learning and a cross-species workflow | Nature Biomedical Engineering</a>
&nbsp;
Recently, MindRank AI, University of Oslo, University of Macau, Imperial College London and other teams published a study &ldquo;Amelioration of Alzheimer&rsquo;s disease pathology by mitophagy inducers identified via machine learning and a cross-species workflow&rdquo; in Nature Biomedical Engineering, a top journal with an impact factor (IF) of 25.6.&nbsp; MindRank AI Team are responsible for the development and verification of AI model in this study. Professor Evandro F. Fang from University of Oslo in Norway and Professor Lu Jiahong from Macau University are responsible for the research design and biological experiments of this study.
In this study, a virtual screening algorithm based on artificial intelligence (AI) integrating multi-dimensional molecular information was established. Meanwhile, combined with the verification of Alzheimer&rsquo;s disease (AD) models in multi-species such as human cells,&nbsp;Caenorhabditis elegans&nbsp;and mice, small molecular compounds of traditional Chinese medicine with AD therapeutic potential were successfully and rapidly screened. In this study, an efficient and feasible AI-based drug discovery scheme is proposed for AD treatment, which provides a new strategy for rapid development of anti-AD drugs.
<img src="https://api.site.mindrank.ai/v1/files/7b4a6969-0a54-42c1-a525-fbf4065c6c0e" alt="" width="605" height="322" />
Li-Huei Tsai, an international authority on Alzheimer&rsquo;s disease research and a professor from the Department of Brain and Cognitive Science of the Massachusetts Institute of Technology (MIT), pointed out: &ldquo;In this study, cutting-edge machine learning algorithms were used to successfully discover new neuronal mitophagy inducers, candidate drugs were screened by using computer, and then verified in multiple systems such as cells, Caenorhabditis elegans and mouse models expressing human P301L Tau protein, and finally two small molecule compounds kaempferol and rhapontigenin were found. It is worth noting that these mitophagy inducers can effectively improve neuronal function, reduce AD-related pathological changes, and enhance learning and memory ability in animal models. Therefore, this study identified an effective mitophagy inducer through computer drug screening and multi-system verification. In addition, their study shows the therapeutic value of mitophagy in protecting neurons and improving memory function.

Nature BME｜Amelioration of Alzheimer’s Disease Pathology by Mitophagy inducers identified via machine learning and a cross-species workflow

The original news link:&nbsp;
<a href="https://equalocean.com/briefing/20211217230104126">AI pharmaceutical company wisdom Medicine completed tens of millions of dollars in round a financing | EqualOcean</a>
&nbsp;
<img src="https://api.site.mindrank.ai/v1/files/946f4b3a-7e97-407b-92b3-c30f5058bf4e" alt="" width="1080" height="459" />
On December 15th, AI pharmaceutical startup MindRank AI completed tens of millions of US dollars in A round financing, which was jointly led by Huagai Capital and Pinevc, and the shareholder Sherpa Healthcare Partners continued to invest. This round of financing will support the company&rsquo;s team expansion, self-research pipeline research and development, as well as business expansion.
Since the angel round of financing in May this year, MindRank AI has applied its self-developed one-stop AI drug R&amp;D platform Molecule Pro&trade;️ and has successfully delivered the R&amp;D milestones to several listed pharmaceutical companies and biotech companies, and has signed further large orders. In the meantime, MindRank AI designed a candidate molecule with best-in-class potential for a listed pharmaceutical company partner, and has entered the follow-up preclinical development (IND-Enabling) stage.
Niu Zhangming, founder and CEO of MindRank AI, said: &ldquo;We hope to advance the boundaries of AI-assisted drug R&amp;D capabilities through the practices of difficult pipelines, continuous technological innovation and algorithm iteration, in order to push the pipelines to clinical use and bring value to the society.&rdquo;
Deng Liang, a partner of Huagai Capital&rsquo;s partner said: &ldquo;MindRank AI has rich experience in new drug research and development and AI pharmaceuticals. Its independent research and development pipeline has made rapid progress in the development of relatively complex targets and has great potential. The new drug AI R&amp;D platform has been recognized by many companies in the industry for cooperation, and at the same time provides an important boost to the self-developed drug pipeline. I look forward to the team&rsquo;s steady development in the new drug R&amp;D field.&rdquo;
Yang Jin, Partner of Pinevc, said: &ldquo;MindRank AI team has gained international recognition in terms of independent development capabilities and technological development. In response to the pain points of new drugs that have attracted much attention, MindRank AI&rsquo;s self-developed one-stop AI-driven drug R&amp;D platform has proved from actual cases that the technology platform has improved the efficiency of R&amp;D and has a strong ability. It is hoped that the pipeline can be promoted into the clinic in the near future to achieve real patient benefits.&rdquo;
Shi Yina, Managing Director of Sherpa Healthcare Partners, said: &ldquo;Since the angel round of investment in May this year, we have witnessed the rapid development of the MindRank AI&rsquo;s pharmaceutical team and business. Its pipeline progress demonstrates the self-developed one-stop AI technology platform to empower new drugs R&amp;D capabilities and potential. We are optimistic about the continued increase and look forward to the team&rsquo;s future breakthroughs in the international AI pharmaceutical field.&rdquo;

MindRank AI has Completed Tens of Millions of US dollars in A Round financing, AI facilitates Drug Pipeline R&D

The original news link in Chinese:
<a href="http://www.medicilon.com.cn/news/AI-pharmaceutical.shtml">用AI赋能肿瘤创新药研发！美迪西与德睿智药达成战略合作_AI_医药研发-上海美迪西生物医药股份有限公司 (medicilon.com.cn)</a>

MindRank AI and Medicilon Preclinical Research LLC (SHA: 688202) Reached a Strategic Cooperation to Develop Innovative Cancer Drugs with AI

The original news link in Chinese:
<a href="https://blogs.nvidia.cn/2021/10/21/mindrank-a100-drug-discovery/">GPU助力德睿智药加速创新药物研发 &ndash; NVIDIA 中国官方博客</a>

MindRank AI was Invited to Join the “NVIDIA Startup Acceleration Program” 

The original news link:&nbsp;
<a href="https://www.antengene.com/news/1553.html">Antengene and MindRank AI Enter into Collaboration to Advance the Development of Difficult-to-Drug Molecular Targets-Antengene</a>
&nbsp;
Shanghai and Hong Kong, PRC, August 9 2021 &ndash; Antengene Corporation Limited (&ldquo;Antengene&rdquo;, SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in-class therapeutics in hematology and oncology; and MindRank AI, an innovative AI drug discovery company, today announced&nbsp;a long-term strategic partnership on the joint development of first-in-class small-molecule oncology drugs. To date, MindRank AI has already made contributions to the development of one of Antengene&rsquo;s pre-clinical stage drug candidates.
This collaboration marks the establishment of a synergistic alliance between a leading research-driven biopharmaceutical company and an innovative AI-powered drug discovery company to transform drug discovery and development. Antengene has a strong R&amp;D team with global experience in the discovery and development of innovative drugs and proven capability in developing compounds for difficult-to-drug targets. To date, Antengene has built a broad and expanding pipeline of 13 clinical and pre-clinical assets, comprising 8 global rights assets and 5 assets with rights for Asia Pacific markets including the Greater China region.&nbsp;Meanwhile, MindRank AI will deploy its proprietary one-stop AI-driven drug discovery platform, Molecule Pro&trade;, and its molecular dynamics platform, Molecule Dance&trade;, to support Antengene&rsquo;s efforts in discovering and developing more first-in-class and best-in-class drug candidates.
Through this collaboration to advance the development of difficult-to-drug targets, Antengene and MindRank AI aim to improve the efficiency and success rate of the current drug discovery process. Both parties hope to address more unmet medical needs by delivering practice-changing therapeutics for patients.
Dr. Jay Mei, Founder, Chairman and CEO of Antengene, commented: &ldquo;We are excited about this ground-breaking partnership with MindRank AI, established to accelerate our development of new therapies for difficult-to-drug targets. Antengene has built a pipeline of 13 assets over the past 4 years through both partnerships and in-house discovery. In 2021, we have seen our first in-house developed asset enter into clinical stage. We are confident that this collaboration between two industry leaders will further enhance our in-house discovery capabilities and bring more novel, broader and effective therapeutics to patients around the world.&rdquo;
Mr. Zhangming Niu, Founder and CEO of MindRank AI, noted: &ldquo;We are very honored to be a strategic partner of Antengene, an industry-leader with robust R&amp;D capabilities and a management team possessing experience in developing and commercializing some of the world&rsquo;s bestselling oncology drugs. We hope this synergistic collaboration of Antengene&rsquo;s deep expertise and MindRank&rsquo;s proprietary AI-powered drug discovery platform will result in more first-in-class oncology drugs for patients globally. Together, we will strive to close more treatment gaps and bring renewed hope to more patients .
About Antengene
Antengene Corporation Limited (&ldquo;Antengene&rdquo;, SEHK: 6996.HK) is a leading clinical-stage R&amp;D-driven biopharmaceutical company focused on innovative medicines for oncology and other life-threatening diseases. Antengene aims to provide the most advanced anti-cancer drugs to patients in the Asia Pacific Region and around the world. Since its establishment in 2017, Antengene has obtained 15 investigational new drug (IND) approvals, submitted 6 new drug applications (NDAs) in multiple Asia Pacific markets, and was granted an NDA approval in South Korea through a priority review process. Leveraging partnerships as well as in-house drug discovery, Antengene has built a broad and expanding pipeline of 13 clinical and pre-clinical assets, comprising 8 global rights assets and 5 assets with rights for Asia Pacific markets including the Greater China region. Driven by its vision of &ldquo;Treating Patients Beyond Borders&rdquo;, Antengene is committed to addressing significant unmet medical needs by discovering, developing, manufacturing and commercializing first-in-class/best-in-class therapeutics.

MindRank AI and Antengene (6996.HK) Enter into Collaboration to Advance the Development of Difficult-to-Drug Molecular Targets

The original news link in Chinese:
&nbsp;<a href="http://www.chemexpress.com.cn/newsDetail_193.html">皓元医药与德睿智药进一步深化合作AI辅助化学合成研发 (chemexpress.com.cn)</a>

MindRank AI and HaoYuan Chemexpress (SHA: 688131) Establish Strategic Colleboration to Develop AI-assisted Chemical Synthesis Platform

The original news link in Chinese:&nbsp;
<a href="https://www.jiqizhixin.com/articles/2021-04-11-3">600多所高校、13000支队伍参赛，这场AI技术创新大赛凭什么风靡全球？ | 机器之心 (jiqizhixin.com)</a>

MindRank AI Win the Championship in the Global Artificial Intelligence Technology Innovation Contest

The original news link:&nbsp;
<a href="https://vcbeat.top/51105">MindRank AI completed $7 Million of seed round fundraising, Sherpa Healthcare Partnersled the investment</a>

News

Track Our News on